Eli Lilly and Given Consensus Recommendation of “Hold” by Brokerages (NYSE:LLY)
Eli Lilly and (NYSE:LLY) has received an average rating of “Hold” from the nineteen brokerages that are presently covering the stock, ARN reports. Three equities research analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $60.46.
Shares of Eli Lilly and (NYSE:LLY) traded down 0.52% during mid-day trading on Tuesday, hitting $59.43. 586,628 shares of the company’s stock traded hands. Eli Lilly and has a 52-week low of $47.53 and a 52-week high of $61.15. The stock has a 50-day moving average of $59.34 and a 200-day moving average of $55.95. The company has a market cap of $63.750 billion and a price-to-earnings ratio of 16.70.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Thursday, April 24th. The company reported $0.70 earnings per share for the quarter, meeting the analysts’ consensus estimate of $0.70. The company had revenue of $4.68 billion for the quarter, compared to the consensus estimate of $4.78 billion. During the same quarter last year, the company posted $1.14 earnings per share. Eli Lilly and’s revenue was down 16.4% compared to the same quarter last year. Analysts expect that Eli Lilly and will post $2.78 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which is scheduled for Tuesday, June 10th. Investors of record on Thursday, May 15th will be paid a dividend of $0.49 per share. This represents a $1.96 annualized dividend and a dividend yield of 3.28%. The ex-dividend date is Tuesday, May 13th.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 190,000 shares of Eli Lilly and stock on the open market in a transaction that occurred on Thursday, June 5th. The shares were sold at an average price of $59.53, for a total transaction of $11,310,700.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Several analysts have recently commented on the stock. Analysts at Morgan Stanley reiterated an “underweight” rating on shares of Eli Lilly and in a research note on Monday, June 2nd. They now have a $48.00 price target on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Eli Lilly and in a research note on Friday, May 16th. They now have a $61.00 price target on the stock. Finally, analysts at Argus reiterated a “buy” rating on shares of Eli Lilly and in a research note on Tuesday, April 29th. They now have a $64.00 price target on the stock.
Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.